(TNGX) Tango Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.068m USD | Total Return: 985.3% in 12m
Avg Turnover: 69.3M
Qual. Beats: 0
Rev. Trend: 55.5%
Qual. Beats: 0
Warnings
Share dilution 30.2% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
Tango Therapeutics, Inc. (TNGX) is a Boston-based biotechnology firm specializing in precision oncology through the discovery and development of targeted therapies. The company’s primary clinical focus centers on methylthioadenosine-cooperative PRMT5 inhibitors, specifically TNG462 for solid tumors and the brain-penetrant TNG456 for glioblastoma. Additionally, the company is advancing TNG260 to address immune evasion in lung cancer patients with STK11 mutations.
The precision oncology sector utilizes a synthetic lethality approach, identifying genetic vulnerabilities in cancer cells to create drugs that spare healthy tissue. This business model typically involves high research and development costs during early-phase clinical trials before seeking regulatory approval or strategic partnerships with larger pharmaceutical entities. Investors may find additional context on these industry trends at ValueRay.
- Clinical trial results for PRMT5 inhibitor TNG462 drive valuation in pancreatic cancer
- Glioblastoma data for brain-penetrant TNG456 determines expansion into central nervous system markets
- Development of TNG260 addresses high unmet need in STK11-mutant lung cancer populations
- Cash runway and burn rate dictate timing of future dilutive equity offerings
- Regulatory approval pathways for precision oncology candidates influence long-term revenue projections
| Net Income: -107.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA 19.33 > 1.0 |
| NWC/Revenue: 663.2% < 20% (prev 461.1%; Δ 202.1% < -1%) |
| CFO/TA -0.32 > 3% & CFO -141.5m > Net Income -107.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 27.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (143.6m) vs 12m ago 30.17% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 16.05% > 50% (prev 14.94%; Δ 1.11% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 392.3m - Total Current Liabilities 14.3m) / Total Assets 435.8m |
| B: -1.49 (Retained Earnings -648.7m / Total Assets 435.8m) |
| C: -0.32 (EBIT TTM -115.4m / Avg Total Assets 355.0m) |
| D: -14.65 (Book Value of Equity -648.6m / Total Liabilities 44.3m) |
| Altman-Z'' = -16.73 = D |
As of May 24, 2026, the stock is trading at USD 21.62 with a total of 2,499,710 shares traded.
Over the past week, the price has changed by -1.56%,
over one month by -24.87%,
over three months by +58.99% and
over the past year by +985.25%.
Tango Therapeutics has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy TNGX.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.9 | 47.5% |
P/B = 7.7809
Revenue TTM = 57.0m USD
EBIT TTM = -115.4m USD
EBITDA TTM = -113.3m USD
Long Term Debt = 30.0m USD (estimated: total debt 32.8m - short term 2.83m)
Short Term Debt = 2.83m USD (from shortTermDebt, last quarter)
Debt = 32.8m USD (from shortLongTermDebtTotal, last quarter) (leases 32.8m already included)
Net Debt = -347.1m USD (calculated: Debt 32.8m - CCE 379.8m)
Enterprise Value = 2.72b USD (3.07b + Debt 32.8m - CCE 379.8m)
Interest Coverage Ratio = unknown (Ebit TTM -115.4m / Interest Expense TTM 0.0)
EV/FCF = -35.74x (Enterprise Value 2.72b / FCF TTM -76.1m)
FCF Yield = -2.80% (FCF TTM -76.1m / Enterprise Value 2.72b)
FCF Margin = -133.6% (FCF TTM -76.1m / Revenue TTM 57.0m)
Net Margin = -188.2% (Net Income TTM -107.2m / Revenue TTM 57.0m)
Gross Margin = unknown ((Revenue TTM 57.0m - Cost of Revenue TTM 2.12m) / Revenue TTM)
Tobins Q-Ratio = 6.24 (Enterprise Value 2.72b / Total Assets 435.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 32.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -91.1m (EBIT -115.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 23.41 (Total Current Assets 392.3m / Total Current Liabilities 16.8m)
Debt / Equity = 0.08 (Debt 32.8m / totalStockholderEquity, last quarter 391.5m)
Debt / EBITDA = 3.06 (negative EBITDA) (Net Debt -347.1m / EBITDA -113.3m)
Debt / FCF = 4.56 (negative FCF - burning cash) (Net Debt -347.1m / FCF TTM -76.1m)
Total Stockholder Equity = 258.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.20% (Net Income -107.2m / Total Assets 435.8m)
RoE = -11.82% (Net Income TTM -107.2m / Total Stockholder Equity 906.8m)
RoCE = -12.32% (EBIT -115.4m / Capital Employed (Equity 906.8m + L.T.Debt 30.0m))
RoIC = -51.47% (negative operating profit) (NOPAT -91.1m / Invested Capital 177.1m)
WACC = 9.61% (E(3.07b)/V(3.10b) * Re(9.71%) + D(32.8m)/V(3.10b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 19.70%
[DCF] Fair Price = unknown (Cash Flow -76.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.38 | # QB: 0
Revenue Correlation: 55.45 | Revenue CAGR: 18.74% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.33 | Chg30d=+0.00% | Revisions=+0% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.34 | Chg30d=-3.00% | Revisions=+0% | Analysts=11
EPS current Year (2026-12-31): EPS=-1.35 | Chg30d=-0.66% | Revisions=-11% | GrowthEPS=-54.8% | GrowthRev=-100.0%
EPS next Year (2027-12-31): EPS=-1.58 | Chg30d=+1.06% | Revisions=+11% | GrowthEPS=-17.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -11%